Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with a corticosteroid.

Provided herein are, inter alia, methods for treating rhinosinusitis with P-glycoprotein inhibitors. A subject having rhinosinusitis is identified and then treated by administration to the subject an effective amount of a P-gp inhibitor. The subject having rhinosinusitis can be identified by one of skill in the art based on known methods, e.g., based on detection of the presence of symptoms, by endoscopy, or by computed tomography. The efficacy of the treatment can be monitored by methods known in the art, e.g., by monitoring symptoms, by endoscopy or computed tomography. The P-glycoprotein inhibitor can be delivered to the subject's nasal passage and sinuses by an inhalation device, by flushing, by spraying, or by an eluting implant surgically placed in the subject's nasal passage or sinuses. The P-glycoprotein inhibitor can also be administered in combination with a corticosteroid.

The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.

The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.

The application relates to a medicament carrier which is suitable for the treatment and prevention of pathological conditions in the urogenital region of a person, in particular in the area of the urethra. Said medicament carrier comprises a biocompatible material that cannot melt at the person's body temperature. The medicament carrier is prepared, e.g. at least partially coated, with an active substance or with a mixture of active substances. The medicament carrier is provided with a recovery string (6) for removing same from the body orifice after completion of the treatment. Active substances can be administered generally in the urogenital region using the medicament carrier. The medicament carrier can also be used for microbial reconstitution of the urogenital tract and for sterile catheterization.

The application relates to a medicament carrier which is suitable for the treatment and prevention of pathological conditions in the urogenital region of a person, in particular in the area of the urethra. Said medicament carrier comprises a biocompatible material that cannot melt at the person's body temperature. The medicament carrier is prepared, e.g. at least partially coated, with an active substance or with a mixture of active substances. The medicament carrier is provided with a recovery string (6) for removing same from the body orifice after completion of the treatment. Active substances can be administered generally in the urogenital region using the medicament carrier. The medicament carrier can also be used for microbial reconstitution of the urogenital tract and for sterile catheterization.

Provided herein are compositions, systems, kits, and methods for treating cancer in a subject with androgen receptor positive cancer cells by sensitizing such cancer cells with anti-androgen receptor therapy (e.g., Enzalutamide or anti-androgen antibody), and then treating with radiation therapy.

Provided herein are compositions, systems, kits, and methods for treating cancer in a subject with androgen receptor positive cancer cells by sensitizing such cancer cells with anti-androgen receptor therapy (e.g., Enzalutamide or anti-androgen antibody), and then treating with radiation therapy.

This document provides methods and materials for detecting and/or treating endometrial hyperplasia and/or endometrial cancer. For example, this document provides methods and materials for identifying a female mammal as having endometrial hyperplasia and administering a therapy (e.g., hormone therapy) to the female mammal. For example, this document provides methods and materials for identifying a female mammal as having endometrial cancer and surgically removing at least the uterus of the female mammal.

Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidases SpsB and/or LepB, an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.